Manufacturer: Novartis

Indications: Zoledronic acid injection is indicated for patients with hypercalcemia of malignancy, for patients with multiple myeloma, and for patients with documented bone metastases from solid tumors, in conjunction with standard antineoplas-tic therapy. Prostate cancer should improve after treatment with at least one hormonal therapy.

…..Click here to read more

Manufacturer: Jones Pharma, Inc. Indications: Levothyroxine canadian has several uses:

• As replacement or supplemental therapy in patients with congenital or acquired hypothyroidism of any cause, except transient hypothyroidism during the recovery phase of subacute thyroiditis.
• Suppression of pituitary thyroid-stimulating hormone (TSH) to treat or prevent various types of euthyroid goiters, subacute or chronic lymphocytic thyroiditis (e.g., Hashimoto’s thyroiditis), or multinodule goiter.
• As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent, well-differentiated thyroid cancer.

…..Click here to read more

Manufacturer: Biogen and Genentech

Indications: Rituximab is indicated for relapsed or refractory low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s lymphoma and for diffuse, CD20-positive, large B-cell non-Hodgkin’s lymphoma in combination with CHOP (cyclo-phosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.

…..Click here to read more

Efavirenz (Sustiva generic)

Manufacturer: Bristol-Myers Squibb Indication: This prescription-only agent is used in combination with other medications to treat human immunodeficiency virus (HIV) infection. Reason for FDA Intervention: The product’s labeling has been revised to include safety and efficacy data representing 168 weeks of treatment from Study 006 and other available information.

…..Click here to read more

Speaker: Douglas T. Dieterich, MD, Vice Chair and Chief Medical Officer, Department of Medicine, and Professor of Medicine, Mount Sinai Medical Center, New York, New York

Patients who are co-infected with HIV and hepatitis C virus (HCV) who achieve a sustained virological response with peginterferon alfa-2a (Pegasys®, Roche) and ribavirin generic (Rebe-tol®, Schering) combination therapy have a much improved health-related quality of life (HRQL) compared with co-infected patients who remain HCV-positive.

…..Click here to read more

Speaker: Charles Hicks, MD, Associate Professor of Medicine, Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina

Tipranavir (TPV) (Boehringer Ingelheim), a novel non-peptidic protease inhibitor (PI), now in late phase 3 clinical development, plus low-dose ritonavir(r) (Norvir drug, Abbott) was found to be significantly superior to currently available comparator protease inhibitors (CPIs) boosted by ritonavir (CPI/r). After 24 weeks of treatment, the virus was suppressed in patients with advanced HIV disease who had been exposed to more than three antiretroviral agents.

…..Click here to read more

Speaker: Beth L. Nordstrom, PhD, Epidemiologist, Ingenix Epidemiology, Aburndale, Massachusetts

In a large population of patients with influenza, treatment with oseltamivir (Drug Tamiflu, Hoffman-LaRoche Ltd.) was associated with a significant reduction in the risk of pneumonia. Several clinical studies showed that oseltamivir was up to 92% effective in preventing influenza in adolescents, adults, and elderly adults when it was taken once daily for seven days. These studies suggested that the risk of pneumonia and other sequelae of influenza might be decreased in patients who used this agent.

…..Click here to read more